|
1
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pan Z, Cai J, Lin J, Zhou H, Peng J, Liang
J, Xia L, Yin Q, Zou B, Zheng J, et al: A novel protein encoded by
circFNDC3B inhibits tumor progression and EMT through regulating
Snail in colon cancer. Mol Cancer. 19:712020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spaderna S, Schmalhofer O, Hlubek F, Berx
G, Eger A, Merkel S, Jung A, Kirchner T and Brabletz T: A
transient, EMT-linked loss of basement membranes indicates
metastasis and poor survival in colorectal cancer.
Gastroenterology. 131:830–840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi M, Liu Y, Feng L, Cui Y, Chen Y, Wang
P, Wu W, Chen C, Liu X and Yang W: Protective effects of
scutellarin on human cardiac microvascular endothelial cells
against hypoxia-reoxygenation injury and its possible
target-related proteins. Evid Based Complement Alternat Med.
2015:2780142015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hallal S, Russell BP, Wei H, Lee MY, Toon
CW, Sy J, Shivalingam B, Buckland ME and Kaufman KL: Extracellular
vesicles from neurosurgical aspirates identifies chaperonin
containing TCP1 subunit 6A as a potential glioblastoma biomarker
with prognostic significance. Proteomics. 19:e18001572019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang J, Liu C, Xu G, Liang T, Yu C, Liao
S, Zhang Z, Lu Z, Wang Z, Chen J, et al: CCT6A, a novel prognostic
biomarker for Ewing sarcoma. Medicine (Baltimore). 100:e244842021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeng G, Wang J and Huang Y, Lian Y, Chen
D, Wei H, Lin C and Huang Y: Overexpressing CCT6A contributes to
cancer cell growth by affecting The G1-To-S phase transition and
predicts a negative prognosis in hepatocellular carcinoma. Onco
Targets Ther. 12:10427–10439. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu M, Fu X, Si Z, Li C, Sun J, Du X and
Zhang H: Identification of differently expressed genes associated
with prognosis and growth in colon adenocarcinoma based on
integrated bioinformatics analysis. Front Genet. 10:12452019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Myung JK, Afjehi-Sadat L,
Felizardo-Cabatic M, Slavc I and Lubec G: Expressional patterns of
chaperones in ten human tumor cell lines. Proteome Sci. 2:82004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu J, Li S, Cheng X, Du P, Yang Y and
Jiang WG: HOXB2 is a Putative tumour promotor in human bladder
cancer. Anticancer Res. 39:6915–6921. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Inamura K, Togashi Y, Ninomiya H, Shimoji
T, Noda T and Ishikawa Y: HOXB2, an adverse prognostic indicator
for stage I lung adenocarcinomas, promotes invasion by
transcriptional regulation of metastasis-related genes in HOP-62
non-small cell lung cancer cells. Anticancer Res. 28:2121–2127.
2008.PubMed/NCBI
|
|
13
|
Clemenceau A, Boucherat O, Landry-Truchon
K, Lamontagne M, Biardel S, Joubert P, Gobeil S, Secco B, Laplante
M, Morissette M, et al: Lung cancer susceptibility genetic variants
modulate HOXB2 expression in the lung. Int J Dev Biol. 62:857–864.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Segara D, Biankin AV, Kench JG, Langusch
CC, Dawson AC, Skalicky DA, Gotley DC, Coleman MJ, Sutherland RL
and Henshall SM: Expression of HOXB2, a retinoic acid signaling
target in pancreatic cancer and pancreatic intraepithelial
neoplasia. Clin Cancer Res. 11:3587–3596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Zhu G, Xing Y, Zhu Y and Piao D:
MiR-4324 functions as a tumor suppressor in colorectal cancer by
targeting HOXB2. J Int Med Res. 48:3000605198837312020.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Walter V, Boakye D, Weberpals J, Jansen L,
Haefeli WE, Martens UM, Knebel P, Chang-Claude J, Hoffmeister M and
Brenner H: Decreasing use of chemotherapy in older patients with
stage iii colon cancer irrespective of comorbidities. J Natl Compr
Canc Netw. 17:1089–1099. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Shi J, Huang H, Ren J, Li N and
Dai M: Burden of colorectal cancer in China. Zhonghua Liu Xing Bing
Xue Za Zhi. 36:709–714. 2015.(In Chinese). PubMed/NCBI
|
|
19
|
Cheng B, Rong A, Zhou Q and Li W: LncRNA
LINC00662 promotes colon cancer tumor growth and metastasis by
competitively binding with miR-340-5p to regulate CLDN8/IL22
co-expression and activating ERK signaling pathway. J Exp Clin
Cancer Res. 39:52020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
AlMutairi M, Parine NR, Shaik JP, Aldhaian
S, Azzam NA, Aljebreen AM, Alharbi O, Almadi MA, Al-Balbeesi AO and
Alanazi M: Association between polymorphisms in PRNCR1 and risk of
colorectal cancer in the Saudi population. PLoS One.
14:e02209312019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen
S, Wang Y, Wang T and Hou Y: Carcinoma-associated fibroblasts
promote the stemness and chemoresistance of colorectal cancer by
transferring exosomal lncRNA H19. Theranostics. 8:3932–3948. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhai X, Xue Q, Liu Q, Guo Y and Chen Z:
Colon cancer recurrence-associated genes revealed by WGCNA
co-expression network analysis. Mol Med Rep. 16:6499–6505. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu Q, Meng WY, Jie Y and Zhao H: LncRNA
MALAT1 induces colon cancer development by regulating
miR-129-5p/HMGB1 axis. J Cell Physiol. 233:6750–6757. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang K, Zeng Y, Xie Y, Huang L and Wu Y:
Bioinformatics analysis of the prognostic value of CCT6A and
associated signalling pathways in breast cancer. Mol Med Rep.
19:4344–4352. 2019.PubMed/NCBI
|
|
25
|
Tanic N, Brkic G, Dimitrijevic B,
Dedovic-Tanic N, Gefen N, Benharroch D and Gopas J: Identification
of differentially expressed mRNA transcripts in drug-resistant
versus parental human melanoma cell lines. Anticancer Res.
26:2137–2142. 2006.PubMed/NCBI
|
|
26
|
Ying Z, Tian H, Li Y, Lian R, Li W, Wu S,
Zhang HZ, Wu J, Liu L, Song J, et al: CCT6A suppresses SMAD2 and
promotes prometastatic TGF-β signaling. J Clin Invest.
127:1725–1740. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu HY and Pan SS: MiR-202-5p suppressed
cell proliferation, migration and invasion in ovarian cancer via
regulating HOXB2. Eur Rev Med Pharmacol Sci. 24:2256–2263.
2020.PubMed/NCBI
|
|
28
|
Lee JY, Kim JM, Jeong DS and Kim MH:
Transcriptional activation of EGFR by HOXB5 and its role in breast
cancer cell invasion. Biochem Biophys Res Commun. 503:2924–2930.
2018. View Article : Google Scholar : PubMed/NCBI
|
